Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12049728 | 0.89 | NPC1 (0.38) | CHRM1CHRM3CHRM4CHRM5CHRM2 | |
| SCHEMBL19145360 | 0.82 | CHRM1 (0.34) | CHRM1CHRM3CHRM4CHRM5CHRM2 | |
| SCHEMBL13172002 | 0.79 | CHRM1 (0.36) | CHRM1CHRM3CHRM4CHRM5CHRM2 | |
| SCHEMBL12886875 | 0.79 | CHRM1 (0.36) | CHRM1CHRM3CHRM4CHRM5CHRM2 | |
| SCHEMBL12886625 | 0.79 | CHRM1 (0.36) | CHRM1CHRM3CHRM4CHRM5CHRM2 | |
| SCHEMBL18912346 | 0.77 | KMT2A (0.36) | CHRM1CHRM3CHRM4CHRM5CHRM2 | |
| SCHEMBL14971167 | 0.77 | CHRM1 (0.37) | CHRM1CHRM3CHRM4CHRM5CHRM2 | |
| SCHEMBL13561506 | 0.77 | CHRM1 (0.37) | CHRM1CHRM3CHRM4CHRM5CHRM2 | |
| SCHEMBL13561507 | 0.77 | KMT2A (0.36) | CHRM1CHRM3CHRM4CHRM5CHRM2 | |
| SCHEMBL13162853 | 0.77 | KMT2A (0.36) | CHRM1CHRM3CHRM4CHRM5CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166135-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166135-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | PDE10A, PDE3A, PDE3B | CHRM1 138/4885CHRM3 143/4885CHRM4 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.